Marjani Majid, Fahim Fanak, Sadr Makan, Kazempour Dizaji Mehdi, Moniri Afshin, Khabiri Shadi, Tabarsi Payam, Velayati Ali Akbar
Clinical Tuberculosis and Epidemiology Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Department of Clinical Pharmacy, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Gastroenterol Hepatol Bed Bench. 2019 Spring;12(2):138-142.
This study was performed to evaluate the potential efficacy of silymarin in the management of anti-tuberculosis medication's induced liver injury.
Hepatic toxicity is the most serious complication in treatment of tuberculosis.
In a randomized double blind clinical trial (ACTRN12610000643077), 55 cases with hepatotoxicity caused by anti-tuberculosis drugs were divided into two groups. Informed consents were obtained. The intervention group received silymarin and the control group received placebo. Severity of liver injury, the duration necessary for normalization of liver function and hospital stay were compared between the two groups.
There was not any statistically significant difference in the rate of adverse effects between silymarin and placebo groups.
Although silymarin is considered a safe herbal medication, it was not effective to treat hepatic toxicity of anti-tuberculosis drugs.
本研究旨在评估水飞蓟素在治疗抗结核药物所致肝损伤方面的潜在疗效。
肝毒性是结核病治疗中最严重的并发症。
在一项随机双盲临床试验（澳大利亚临床试验注册号：ACTRN12610000643077）中，将55例由抗结核药物引起肝毒性的患者分为两组。获得了知情同意书。干预组接受水飞蓟素治疗，对照组接受安慰剂治疗。比较两组肝损伤的严重程度、肝功能恢复正常所需的时间以及住院时间。
水飞蓟素组和安慰剂组之间的不良反应发生率没有任何统计学上的显著差异。
尽管水飞蓟素被认为是一种安全的草药药物，但它对治疗抗结核药物所致的肝毒性无效。
Zotero 插件